Sprint Bioscience (SPRINT) Q2 2026 earnings summary

Executive summary

• No sales revenue reported for Q2 or H1 2026, compared to 13.9 MSEK and 28.0 MSEK in the same periods last year, due to absence of research financing and external cost reimbursements.

• Operating loss widened to -16.6 MSEK in Q2 and -30.9 MSEK in H1 2026, mainly from lack of revenue despite reduced costs.

• Positive proof-of-concept results in the NNMT program expanded its scope to chronic kidney disease.

• Strategic evaluation of the STK25 program completed, maintaining focus on MASH.

• New CFO and board member appointed; partnership with Lilly TuneLab announced post-period.

Financial highlights

• Q2 2026 net sales: 0 MSEK (13.9 MSEK Q2 2025); H1 2026 net sales: 0 MSEK (28.0 MSEK H1 2025).

• Q2 2026 operating result: -16.6 MSEK (-6.8 MSEK Q2 2025); H1 2026: -30.9 MSEK (-11.8 MSEK H1 2025).

• Net result after tax: -16.2 MSEK in Q2 (-7.4 MSEK Q2 2025); -29.1 MSEK in H1 (-13.0 MSEK H1 2025).

• Cash flow from operations: -14.6 MSEK in Q2 (-12.2 MSEK Q2 2025); -33.0 MSEK in H1 (-18.4 MSEK H1 2025).

• Cash and cash equivalents at period end: 93.3 MSEK (24.7 MSEK Q2 2025).

Outlook and guidance

• Continued focus on advancing preclinical programs, especially NNMT and DCPS, with growing scientific validation and external interest.

• Partnership with Lilly TuneLab expected to accelerate AI-driven drug development.